News

Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround

  • AEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
    05/29/2024

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

  • Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline
    05/29/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

AEON Biopharma, Inc. (AEON) can sell. Click on Rating Page for detail.

The price of AEON Biopharma, Inc. (AEON) is 2.63 and it was updated on 2024-07-27 07:01:10.

Currently AEON Biopharma, Inc. (AEON) is in undervalued.

News
    
News

AEON Biopharma Reports First Quarter 2024 Financial Results

  • – Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints –
    Tue, May. 14, 2024

AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

  • AEON Biopharma, Inc. (AEON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
    Thu, May. 09, 2024

AEON Biopharma Provides Update on Development Pipeline

  • Includes two late-stage clinical programs and two early-stage clinical programs Includes two late-stage clinical programs and two early-stage clinical programs
    Thu, May. 09, 2024

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

  • IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint.
    Fri, May. 03, 2024

Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now

  • After losing some value lately, a hammer chart pattern has been formed for AEON Biopharma, Inc. (AEON), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
    Fri, Apr. 19, 2024
SEC Filings
SEC Filings

AEON Biopharma, Inc. (AEON) - SC 13D/A

  • SEC Filings
  • 08/22/2023

AEON Biopharma, Inc. (AEON) - DEL AM

  • SEC Filings
  • 08/22/2023

AEON Biopharma, Inc. (AEON) - S-1

  • SEC Filings
  • 08/18/2023

AEON Biopharma, Inc. (AEON) - 8-K/A - Current report

  • SEC Filings
  • 08/11/2023

AEON Biopharma, Inc. (AEON) - SC 13G

  • SEC Filings
  • 07/31/2023

AEON Biopharma, Inc. (AEON) - SC 13D

  • SEC Filings
  • 07/31/2023

AEON Biopharma, Inc. (AEON) - SC 13D

  • SEC Filings
  • 07/28/2023

AEON Biopharma, Inc. (AEON) - 8-K - Current report

  • SEC Filings
  • 07/27/2023

AEON Biopharma, Inc. (AEON) - RW

  • SEC Filings
  • 12/29/2021

AEON Biopharma, Inc. (AEON) - S-1/A

  • SEC Filings
  • 10/07/2021

AEON Biopharma, Inc. (AEON) - S-1/A

  • SEC Filings
  • 10/06/2021

AEON Biopharma, Inc. (AEON) - S-1/A

  • SEC Filings
  • 10/04/2021

AEON Biopharma, Inc. (AEON) - S-1

  • SEC Filings
  • 09/17/2021

AEON Biopharma, Inc. (AEON) - DRS/A

  • SEC Filings
  • 09/14/2021

AEON Biopharma, Inc. (AEON) - DRS/A

  • SEC Filings
  • 07/21/2021

AEON Biopharma, Inc. (AEON) - DRS/A

  • SEC Filings
  • 06/08/2021

AEON Biopharma, Inc. (AEON) - D/A

  • SEC Filings
  • 05/13/2021

AEON Biopharma, Inc. (AEON) - D

  • SEC Filings
  • 08/31/2020

AEON Biopharma, Inc. (AEON) - DRS/A

  • SEC Filings
  • 03/23/2020

AEON Biopharma, Inc. (AEON) - DRS/A

  • SEC Filings
  • 02/12/2020

AEON Biopharma, Inc. (AEON) - SC 13G/A

  • SEC Filings
  • 01/17/2020

AEON Biopharma, Inc. (AEON) - DRS

  • SEC Filings
  • 12/27/2019

AEON Biopharma, Inc. (AEON) - SC 13G

  • SEC Filings
  • 02/14/2019

AEON Biopharma, Inc. (AEON) - D

  • SEC Filings
  • 08/10/2016

AEON Biopharma, Inc. (AEON) - D

  • SEC Filings
  • 11/20/2015

AEON Biopharma, Inc. (AEON) - D

  • SEC Filings
  • 01/22/2015
Press Releases
StockPrice Release

Aeon biopharma announces strategic resource reprioritization and cost reduction plan

  • 05/29/2024

Aeon biopharma reports first quarter 2024 financial results

  • 05/14/2024

Aeon biopharma provides update on development pipeline

  • 05/09/2024

Aeon biopharma announces preliminary top-line results from phase 2 interim analysis of abp-450 in the preventive treatment of chronic migraine

  • 05/03/2024

Correction -- aeon biopharma announces redemption of public warrants

  • 03/30/2024

Aeon biopharma announces redemption of public warrants

  • 03/29/2024

Aeon biopharma reports fourth quarter and full year 2023 financial results

  • 03/29/2024

Aeon biopharma announces clinical update and productive end-of-phase 2 meeting with fda on abp-450 (prabotulinumtoxina) for the preventive treatment of migraine

  • 03/19/2024

Aeon biopharma announces $15 million financing transaction and termination of forward purchase agreements

  • 03/19/2024

Aeon biopharma presents positive clinical and pre-clinical data for abp-450 (prabotulinumtoxina) in treating cervical dystonia and ptsd, respectively, at a leading neurotoxin conference

  • 01/18/2024

Aeon biopharma completes enrollment in phase 2 study of abp-450 (prabotulinumtoxina) for preventive treatment of chronic migraine

  • 12/12/2023

Aeon biopharma reports third quarter 2023 financial results

  • 11/13/2023

Aeon biopharma announces topline results from phase 2 trial of abp-450 (prabotulinumtoxina) for the preventive treatment of episodic migraine

  • 10/19/2023

Aeon biopharma presents positive results from phase 2 clinical trial of abp-450 (prabotulinumtoxina) in cervical dystonia at the international parkinson and movement disorders society congress®

  • 08/29/2023

Aeon biopharma receives notice of allowance from uspto for a patent covering use of botulinum toxins to treat migraine headache

  • 08/24/2023

Strathspey crown holdings group, llc provides clarifying statement regarding form 4 filing with sec for holdings in aeon biopharma

  • 08/16/2023
More Headlines
News

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

  • IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first paragraph it incorrectly referenced March 29, 2024 as the Redemption Date. The Redemption Date is April 29, 2024. March 29, 2024 is the date on which the notice of redemption was delivered to warrant holders. The corrected release follows:
  • 03/30/2024

AEON Biopharma Announces Redemption of Public Warrants

  • IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the Company will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of the Company's Class A common stock, par value $0.0001 per share (the “Common Stock”), that were issued under the Warrant Agreement, dated February 8, 2021 (the “Warrant Agreement”), by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the “Warrant Agent”), as part of the units sold in the Company's initial public offering (the “IPO”), for a redemption price of $0.10 per Public Warrant (the “Redemption Price”), that remain outstanding at 5:00 p.m. New York City time on March 29, 2024 (the “Redemption Date”). Warrants to purchase Common Stock that were issued under the Warrant Agreement in a private placement simultaneously with the IPO and still held by the initial holders thereof or their permitted transferees are not subject to this redemption.
  • 03/29/2024

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

  • – Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –
  • 03/29/2024

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

  • – FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –
  • 03/19/2024

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

  • -- Termination of the Forward Purchase Agreements simplifies AEON's capitalization structure -- -- AEON to expand its Board of Directors with appointment of candidate selected by its strategic partner following full funding of transaction --
  • 03/19/2024

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

  • – Open label extension (OLE) Phase 2 data show peak efficacy for all ABP-450 doses and cycles in treating cervical dystonia (CD) occurred early, within 4 weeks; durability of effect was demonstrated 12 to 16 weeks post treatment –
  • 01/18/2024

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

  • – Expect to announce topline data in Q3 2024 – – Company plans in Q1 2024 an end-of-phase 2 meeting with the FDA to discuss the Phase 3 program in episodic migraine – – Anticipate shortening the open label extension (OLE) study to 2 treatment cycles – IRVINE, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced today completion of enrollment with the last patient first visit in the Phase 2 study of ABP-450 for the preventive treatment of chronic migraine.
  • 12/12/2023

AEON Biopharma Reports Third Quarter 2023 Financial Results

  • – Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study –
  • 11/13/2023

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

  • – ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not meet statistical significance vs. placebo because of a much higher-than-expected placebo response of 4.2 days –
  • 10/19/2023

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

  • IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced the presentation of positive results from its Phase 2 clinical study of ABP-450 for the treatment of cervical dystonia (CD), a chronic and debilitating neurologic condition affecting the muscles of the neck, at the International Parkinson and Movement Disorders Society Congress® (IP-MDS), which is being held at the Bella Center in Copenhagen, Denmark, from August 27 – 31, 2023. The data was previously released by the Company in September 2022.
  • 08/29/2023

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

  • IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent Application No. 17/006,685, titled “Neurotoxin Compositions for Use in Treating Headache” (the “Application”), which involves the Company's lead asset, ABP-450 (prabotulinumtoxinA) injection. The soon to issue patent will provide protection in the United States for the claimed methods of use of ABP-450 into 2041.
  • 08/24/2023

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

  • The 7,380,394 AEON shares reflected in the Form 4 filed on August 14 th  were transferred to limited partners of Strathspey Crown
  • 08/16/2023

Atalaya Capital Management LP Acquires New Stake in AEON Biopharma Inc

  • Atalaya Capital Management LP (Trades, Portfolio), a New York-based investment firm, recently made a significant acquisition in AEON Biopharma Inc. This article will delve into the details of the transaction, provide an overview of both Atalaya Capital Management LP (Trades, Portfolio) and AEON Biopharma Inc, and analyze the potential impact of this acquisition on the firm's portfolio and the traded company's stock performance.
  • 07/31/2023

Priveterra Acquisition says it will list on NYSE after AEON combination

  • Priveterra Acquisition said that following its planned business combination with AEON Biopharma the combined company will list on the New York Stock Exchange.
  • 07/11/2023

AEON Thana Sinsap (Thailand) : quaterly earnings release | MarketScreener

  • 06/30/2020
Unlock
AEON Ratings Summary
AEON Quant Ranking